Sareum shares fall following interims and research update

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update.

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update.

Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activities after taxation of £269,000. This was less than the reduction reported a year earlier, worth £327,000.

In a separate research update, progress reports were given for a number of the company's programmes showing the level of development that had been measured as well as existing and expected funding options.

Describing the programme known as "VEGFR-3 (FLT4)", the company said: "We have prioritised our research spend on other programmes whilst we investigate grant funding opportunities alongside a partner with the necessary biology expertise to assist us in the progression of this programme."

More detailed updates were given on the company's other programmes. Safety pharmacology studies performed to date on the "Chk1" programme's pre-clinical development candidate were described as "favourable". Oral bio-availability was demonstrated in three species, strengthening its expectation that the compound would be able to be administered via the oral route in future clinical studies.

Head-to-head studies were continuing between two advanced lead molecules as part of the "Aurora+FLT3" with the aim of selecting a pre-clinical development candidate by the middle of the year.

The company further reported that its lead optimisation studies and further compounds had been synthesised with improved potency and selectivity on the "TYK2" programme.

Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "Our ongoing progress in our research programmes is very encouraging and we continue to discuss the commercialisation of these programmes with a number of interested parties.

"We are also now in a strong position to develop our programmes to later stages, should we so choose, which should mean a greater share of the end rewards and we will continue to consider this aspect alongside our various discussions with potential partners."

Sareum's share price was down 14.67% to 1.60p at 08:44 on Monday.

MF

Recommended

Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
25 Nov 2022
Share tips of the week – 25 November
Share tips

Share tips of the week – 25 November

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
25 Nov 2022
Investing in a recession: 5 moves investors should make now
Investment strategy

Investing in a recession: 5 moves investors should make now

As we enter a recession, here’s what investors should do with their portfolios.
23 Nov 2022
It’s time to focus on Fuller’s
Share tips

It’s time to focus on Fuller’s

The pub sector has had a torrid two years, but this group is resilient and poised to prosper. We take a closer look at Fuller’s.
21 Nov 2022

Most Popular

Fan heater vs oil heater – which is cheaper?
Personal finance

Fan heater vs oil heater – which is cheaper?

Sales of portable heaters have soared, as households look to cut their energy costs. But which is better: a fan heater or an oil heater? We put them t…
21 Nov 2022
Wood-burning stove vs central heating ‒ which is cheapest?
Personal finance

Wood-burning stove vs central heating ‒ which is cheapest?

Demand for wood-burning stoves has surged as households try to reduce their heating costs this winter. But how does a wood burner compare with central…
29 Nov 2022
Best regular savings accounts – November 2022
Savings

Best regular savings accounts – November 2022

You can earn an attractive rate on the best regular savings accounts. We tell you the best on the market to take advantage of right now
29 Nov 2022